Patents by Inventor Rafael A. Ponce

Rafael A. Ponce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic editing
    Patent number: 11827880
    Abstract: Disclosed herein are compositions that comprise engineered polynucleotides, pharmaceutical compositions comprising the same, methods of making the same, and methods of treatment comprising the compositions that comprise the engineered polynucleotides.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: November 28, 2023
    Assignee: Shape Therapeutics Inc.
    Inventors: David Huss, Prashant Mali, Anupama Lakshmanan, Christopher Nye, Yiannis Savva, Liana Stein, Richard Sullivan, Rafael Ponce, Susan Byrne
  • Therapeutic Editing
    Publication number: 20230044119
    Abstract: Disclosed herein are compositions that comprise engineered polynucleotides, pharmaceutical compositions comprising the same, methods of making the same, and methods of treatment comprising the compositions that comprise the engineered polynucleotides.
    Type: Application
    Filed: December 1, 2020
    Publication date: February 9, 2023
    Inventors: David HUSS, Prashant MALI, Anupama LAKSHMANAN, Christopher NYE, Yiannis SAVVA, Liana STEIN, Richard SULLIVAN, Rafael PONCE, Susan BYRNE
  • IMMUNE MEDIATED CANCER CELL DESTRUCTION, SYSTEMS AND METHODS
    Publication number: 20170189098
    Abstract: Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.
    Type: Application
    Filed: November 15, 2016
    Publication date: July 6, 2017
    Inventors: Larry Azure, Charles E. Hill, Andrew L. Azure, Rafael Ponce, Lawrence L. Kunz
  • Immune mediated cancer cell destruction, systems and methods
    Patent number: 9526911
    Abstract: Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: December 27, 2016
    Assignee: LAZURE SCIENTIFIC, INC.
    Inventors: Larry Azure, Charles E. Hill, Andrew L. Azure, Rafael Ponce, Lawrence L. Kunz
  • COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20160051671
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Application
    Filed: January 12, 2015
    Publication date: February 25, 2016
    Applicants: ARES TRADING S.A., ZYMOGENETICS, INC.
    Inventors: Rafael A. Ponce, JR., Herve Broly, Hans Otto Lennart Graffner, Sergio Peano
  • Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
    Patent number: 8956611
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, (rituximab),ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: February 17, 2015
    Assignees: ZymoGenetics, Inc., Ares Trading S.A.
    Inventors: Rafael A. Ponce, Jr., Sergio Peano, Herve Broly, Hans Otto Lennart Graffner
  • COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20150017164
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Application
    Filed: August 18, 2014
    Publication date: January 15, 2015
    Inventors: Rafael A. Ponce, JR., Wayne J. Wallis, Matthew S. Holdren, Linda Zuckerman, Alisa M. Littau, Kirk P. Van Ness, Claudia Penna Rossi, Hans Otto Lennart Graffner
  • Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease
    Patent number: 8852591
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: October 7, 2014
    Assignee: Zymogenetics, Inc.
    Inventors: Rafael A. Ponce, Jr., Wayne J. Wallis, Matthew S. Holdren, Linda Zuckerman, Alisa M. Littau, Kirk P. Van Ness, Claudia Pena Rossi, Hans Otto Lennart Graffner
  • COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20090148442
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Application
    Filed: October 16, 2008
    Publication date: June 11, 2009
    Inventors: Rafael A. Ponce, JR., Herve Broly, Hans Otto Lennart Graffner, Sergio Peano
  • COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20080260737
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 23, 2008
    Inventors: Rafael A. Ponce, Wayne J. Wallis, Matthew S. Holdren, Linda Zuckerman, Alisa M. Littau, Kirk P. Van Ness, Claudia Pena Rossi, Hans Otto Lennart Graffner